Citadel Advisors - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$487,025
-15.6%
412,733
+0.8%
0.00%
Q2 2023$577,071
+41.2%
409,270
+50.2%
0.00%
Q1 2023$408,645
+138.8%
272,430
+86.3%
0.00%
Q4 2022$171,096
+23.1%
146,236
+19.1%
0.00%
Q3 2022$139,000
+152.7%
122,796
+255.5%
0.00%
Q2 2022$55,000
-63.3%
34,542
-64.4%
0.00%
Q1 2022$150,000
-79.9%
97,003
-68.2%
0.00%
Q4 2021$746,000
+74.3%
304,794
+79.2%
0.00%
Q3 2021$428,000
+4.6%
170,056
+18.6%
0.00%
Q2 2021$409,000
-38.2%
143,404
-49.0%
0.00%
Q1 2021$662,000
+771.1%
281,418
+560.7%
0.00%
Q4 2020$76,000
-31.5%
42,596
-66.4%
0.00%
Q2 2020$111,000
+68.2%
126,730
+57.6%
0.00%
Q1 2020$66,000
-22.4%
80,437
-15.3%
0.00%
Q4 2019$85,000
+117.9%
94,980
+141.1%
0.00%
Q3 2019$39,00039,3910.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders